296273-16-0Relevant academic research and scientific papers
Structural development studies of anti-hepatitis C virus agents with a phenanthridinone skeleton
Nakamura, Masahiko,Aoyama, Atsushi,Salim, Mohammed T.A.,Okamoto, Mika,Baba, Masanori,Miyachi, Hiroyuki,Hashimoto, Yuichi,Aoyama, Hiroshi
, p. 2402 - 2411 (2010)
A phenanthridinone skeleton was derived from our previous researches on thalidomide and retinoids as a multi-template for generation of anti-viral lead compounds. Structural development studies focusing on anti-hepatitis C virus activity afforded 5-butyl-2-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenanthridin-6(5H)-one (10) and 5-butylbenzo[b]phenanthridin-6(5H)-one (39), which showed EC50 values of approximately 3.7 and 3.2 μM, respectively.
Structure-activity relationship-guided development of retinoic acid receptor-related orphan receptor gamma (RORγ)-selective inverse agonists with a phenanthridin-6(5H)-one skeleton from a liver X receptor ligand
Nishiyama, Yuko,Nakamura, Masahiko,Misawa, Takashi,Nakagomi, Madoka,Makishima, Makoto,Ishikawa, Minoru,Hashimoto, Yuichi
, p. 2799 - 2808 (2014/05/06)
Retinoic acid receptor-related orphan receptors (RORs), which belong to the nuclear receptor superfamily, regulate many physiological processes, including hepatic gluconeogenesis, lipid metabolism, immune function and circadian rhythm. Since RORs resemble liver X receptors (LXRs) in the fold structure of their ligand-binding domains, we speculated that ROR-mediated transcription might be modulated by LXR ligands, in line with the multi-template hypothesis. Therefore, we screened our LXR ligand library for compounds with ROR ligand activity and identified a novel ROR ligand with a phenanthridin-6(5H)-one skeleton. Structure-activity relationship studies aimed at separating ROR inverse agonistic activity from LXR-agonistic activity enabled us to develop a series of ROR inverse agonists based on the phenanthridin-6(5H)-one skeleton, including a RORγ-selective inverse agonist.
